WO2003082206A3 - Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses - Google Patents

Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses Download PDF

Info

Publication number
WO2003082206A3
WO2003082206A3 PCT/US2003/009460 US0309460W WO03082206A3 WO 2003082206 A3 WO2003082206 A3 WO 2003082206A3 US 0309460 W US0309460 W US 0309460W WO 03082206 A3 WO03082206 A3 WO 03082206A3
Authority
WO
WIPO (PCT)
Prior art keywords
multiple sclerosis
methods
compositions
derived proteins
immunoglobulin derived
Prior art date
Application number
PCT/US2003/009460
Other languages
French (fr)
Other versions
WO2003082206A2 (en
Inventor
David Peritt
George Tracey
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Priority to EP03716871A priority Critical patent/EP1494712A4/en
Priority to AU2003220557A priority patent/AU2003220557A1/en
Publication of WO2003082206A2 publication Critical patent/WO2003082206A2/en
Publication of WO2003082206A3 publication Critical patent/WO2003082206A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to at least one novel multiple sclerosis related human Ig derived protein or specified portion or variant, including isolated nucleic acids that encode at least one multiple sclerosis related Ig derived protein or specified portion or variant, multiple sclerosis related Ig derived protein or specified portion or variants, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.
PCT/US2003/009460 2002-03-26 2003-03-26 Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses WO2003082206A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP03716871A EP1494712A4 (en) 2002-03-26 2003-03-26 Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses
AU2003220557A AU2003220557A1 (en) 2002-03-26 2003-03-26 Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36789602P 2002-03-26 2002-03-26
US60/367,896 2002-03-26

Publications (2)

Publication Number Publication Date
WO2003082206A2 WO2003082206A2 (en) 2003-10-09
WO2003082206A3 true WO2003082206A3 (en) 2004-03-04

Family

ID=28675412

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/009460 WO2003082206A2 (en) 2002-03-26 2003-03-26 Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses

Country Status (3)

Country Link
EP (1) EP1494712A4 (en)
AU (1) AU2003220557A1 (en)
WO (1) WO2003082206A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018195A1 (en) * 2002-03-26 2004-01-29 Griswold Don Edgar Diabetes-related immunoglobulin derived proteins, compositions, methods and uses
JP2007515939A (en) * 2003-05-09 2007-06-21 セントカー・インコーポレーテツド IL-23p40-specific immunoglobulin derived proteins, compositions, methods and uses
WO2007147019A2 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
JP2012504555A (en) * 2008-09-30 2012-02-23 ベイラー リサーチ インスティテュート Methods for reducing B helper T cells to treat autoimmune diseases
ES2550040T3 (en) * 2010-05-27 2015-11-04 Janssen Biotech, Inc. Insulin-like growth factor 1 receptor binding peptides
KR20120093002A (en) * 2011-02-14 2012-08-22 (주)에이티젠 Method for diagnosing cancer and diagnosis kit using measurement of nk cell activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012500A2 (en) * 2000-08-07 2002-02-14 Centocor, Inc. Anti-il-12 antibodies, compositions, methods and uses

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200603997T1 (en) * 1999-03-25 2010-01-21 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing them.
WO2002097048A2 (en) * 2001-05-30 2002-12-05 Centocor, Inc. ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012500A2 (en) * 2000-08-07 2002-02-14 Centocor, Inc. Anti-il-12 antibodies, compositions, methods and uses

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BENSON J. ET AL.: "The role of IL-23 in experimental autoimmune encephalomyelitis", FASEB J., vol. 16, no. 5, 22 March 2002 (2002-03-22), pages A1045, XP002971970 *
BROK H.P.M. ET AL.: "Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody", J. IMMUNOL., vol. 169, 2002, pages 6554 - 6563, XP002971968 *
CUA D.J. ET AL.: "Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain", NATURE, vol. 421, 13 February 2003 (2003-02-13), pages 744 - 748, XP002971969 *
FASSBENDER K. ET AL.: "Increased release of interleukin-12p40 in MS, association with intracerebral inflammation", NEUROLOGY, vol. 51, September 1998 (1998-09-01), pages 753 - 758, XP002971972 *
ICHIKAWA M. ET AL.: "Anti-IL-12 antibody prevents the development and progression of multiple sclerosis-like relapsing-remitting demyelinating disease in NOD mice induced with myelin oligodendrocyte glycoprotein peptide", J. NEUROIMMUNOL., vol. 102, January 2000 (2000-01-01), pages 56 - 66, XP002971971 *
LEONARD J.P. ET AL.: "Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12", J. EXP. MED., vol. 181, January 1995 (1995-01-01), pages 381 - 386, XP002256614 *
See also references of EP1494712A4 *

Also Published As

Publication number Publication date
EP1494712A4 (en) 2006-06-14
AU2003220557A8 (en) 2003-10-13
WO2003082206A2 (en) 2003-10-09
EP1494712A2 (en) 2005-01-12
AU2003220557A1 (en) 2003-10-13

Similar Documents

Publication Publication Date Title
WO2005005604A3 (en) Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
WO2002072788A3 (en) Chronic obstructive pulmonary disease-related immunglobulin derived proteins, compositions, methods and uses
WO2002097048A3 (en) ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
WO2003086451A8 (en) Asthma-related anti-il-13 immunoglobulin derived proteins, compositions, methods and uses
WO2003035847A3 (en) Il-13 mutein proteins, antibodies, compositions, methods and uses
WO2004003147A3 (en) Cngh0004 polypeptides, antibodies, compositions, methods and uses
LUC00121I1 (en)
WO2005081687A3 (en) Human hinge core mimetibodies, compositions, methods and uses
WO2003084477A3 (en) Mammalian cdr mimetibodies, compositions, methods and uses
WO2004002417A3 (en) Mammalian ch1 deleted mimetibodies, compositions, methods and uses
WO2006036745A3 (en) Il-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and uses
WO2005032460A3 (en) Human epo mimetic hinge core mimetibodies, compositions, methods and uses
WO2004101750A3 (en) IL-23p40 SPECIFIC IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
TW200716745A (en) Anti-TNF antibodies, compositions, methods and uses
WO2005097175A3 (en) Human glp-1 mimetibodies, compositions, methods and uses
WO2002012500A3 (en) Anti-il-12 antibodies, compositions, methods and uses
WO2005028511A3 (en) Anti-amyloid antibodies, compositions, methods and uses
WO2002012501A3 (en) Anti-dual integrin antibodies, compositions, methods and uses
WO2002022821A3 (en) Antimicrobial peptides and methods of use
WO2003038041A3 (en) Il-4 mutein proteins, antibodies, compositions, methods and uses
WO2004067567A3 (en) Anti-dengue virus antibodies, compositions, methods and uses
WO2003057821A3 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
WO2003082206A3 (en) Multiple sclerosis-related immunoglobulin derived proteins, compositions, methods and uses
WO2001040313A3 (en) Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
WO2003083071A3 (en) Diabetes-related immunoglobulin derived proteins, compositions, methods and uses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003716871

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003716871

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP